Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.
Actively Recruiting
This research aims to better understand mental health treatments for conditions like depression, OCD, and anxiety depression by analyzing existing patient data from Greenbrook. It focuses on how treatments are used and their effects, using information collected during routine clinical care. The study is observational and retrospective, looking back at past data rather than testing new treatments directly. The analysis includes patients treated with NeuroStar TMS, a non-invasive brain stimulation device, and those treated with Esketamine nasal spray for depression. These treatments are part of the collected data, and the study evaluates their use and outcomes over time without administering any new interventions. Participants data from 2011 onwards will be reviewed to assess changes in clinical outcome scores from before treatment to eight weeks after treatment. Researchers will monitor how these treatments impacted symptoms using recorded clinical scores. The study spans from May 2025 until December 2035, focusing on data already collected during routine care without requiring new visits or treatments from participants.
Actively Recruiting
Researchers are evaluating real-world data to better understand how patient characteristics, symptoms, and treatment parameters affect clinical outcomes with the NeuroStar Transcranial Magnetic Stimulation TMS device. This observational study focuses on patients with depression, obsessive-compulsive disorder, and anxiety depression who have been treated with NeuroStar Advanced TMS Therapy System. The study aims to analyze changes in clinical assessment scores over an 8-week treatment period. The study involves patients who have received treatment with the NeuroStar Advanced TMS Therapy System, a non-invasive brain stimulation device. Data from treatments starting November 1, 2008, onwards will be reviewed retrospectively to explore how factors like age at baseline relate to changes in clinical scores after treatment. The study does not involve new interventions but evaluates existing medical records and treatment outcomes. Participants involvement includes the collection and analysis of their treatment and clinical outcome data over an 8-week period post-treatment. Researchers will assess changes in clinical assessment scores from baseline to post-treatment and correlate these with age and other factors. The study will continue until December 2035, with no direct procedures or interventions required from participants during the study period.